TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Free Report) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 210,500 shares, a growth of 35.1% from the February 13th total of 155,800 shares. Based on an average daily volume of 531,500 shares, the short-interest ratio is presently 0.4 days. Currently, 1.9% of the company’s shares are short sold.
TherapeuticsMD Trading Down 1.6 %
Shares of TXMD stock opened at $0.73 on Monday. TherapeuticsMD has a 1-year low of $0.70 and a 1-year high of $2.61. The stock’s fifty day simple moving average is $1.00 and its 200-day simple moving average is $1.31.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on TherapeuticsMD in a research report on Tuesday, January 14th. They set a “hold” rating on the stock.
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Stories
- Five stocks we like better than TherapeuticsMD
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
- 3 Best Fintech Stocks for a Portfolio Boost
- EU-U.S. Military Shift: A Catalyst for These 3 Stocks
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- How to Build the Ultimate Everything ETF Portfolio
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
